(P036) Patterns of Care and Outcomes of Adjuvant Radiotherapy for Meningiomas: A Surveillance, Epidemiology, and End Results and Medicare-Linked Analysis

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Utilization of adjuvant XRT and SRS remained stable between 2000 and 2010. Male sex, young age, marriage, partial resection, grade II/III tumors, and large tumors predicted for use of adjuvant therapy. For all patients, SRS improved survival compared with craniotomy alone. For patients with incomplete resection, SRS improved survival compared with craniotomy alone and adjuvant XRT. Randomized, prospective clinical trials are needed to better define the role of adjuvant XRT or SRS.

Mark J. Amsbaugh, MD, Beatrice Ugiliweneza, PhD, MSPH, Eric Burton, MD, Maxwell Boakye, MD, MPH, MBA, Shiao Woo, MD; University of Louisville

PURPOSE: To identify patterns of care and outcomes of adjuvant radiotherapy for meningiomas in the linked Surveillance, Epidemiology, and End Results (SEER) Medicare data.

MATERIALS AND METHODS: Patients over 66 years of age, diagnosed with meningioma, and treated with a craniotomy in the SEER-Medicare data were included. Patients were grouped according to adjuvant treatment with fractionated radiotherapy (XRT), stereotactic radiosurgery (SRS), or none. Demographic, tumor, treatment, and outcome variables were collected. The Mann-Whitney U-test and chi-square test were used to analyze continuous and categorical variables. Time to event was analyzed with the Kaplan-Meier methods and log-rank test. Multivariate comparisons were conducted with logistic regression and proportional hazard models.

RESULTS: A total of 1,964 patients were included for analysis (1,701 with no adjuvant treatment, 175 with XRT, and 88 with SRS). Patients were less likely to receive adjuvant therapy if they were older than 75 years (odds ratio [OR] = 0.730; 95% confidence interval [CI], 0.548–0.973), female (OR = 0.731; 95% CI, 0.547–0.978), or unmarried (OR = 0.692; 95% CI, 0.515–0.929). Patients were more likely to receive adjuvant treatment for grade II/III tumors (OR = 5.586; 95% CI, 2.135–13.589), tumors over 5 cm (OR = 1.850; 95% CI, 1.332–2.567) or partial resection (OR = 3.230; 95% CI, 2.327–4.484). For those receiving adjuvant therapy, SRS was less likely than XRT in patients diagnosed with grade II/III tumors (OR = 0.061; 95% CI, 0.006–0.655) or a 1-unit increase in Gagne comorbidity score (OR = 0.761; 95% CI, 0.599–0.968). Yearly between 2000 and 2010, 10.65% to 19.77% of patients received adjuvant therapy (7.143%–42.105% of those who received SRS). Although no survival benefit was seen with the addition of adjuvant therapy (P = .1236), the subgroup of patients receiving SRS had better survival compared with those receiving surgery alone (adjusted hazard ratio [aHR] = 0.544; 95% CI, 0.318–0.929). Furthermore, when stratifying patients by degree of resection, those who underwent partial or local resection and did not receive SRS had an increased risk of death compared with those who did (aHR = 1.934; 95% CI, 0.992–3.771).

CONCLUSIONS: Utilization of adjuvant XRT and SRS remained stable between 2000 and 2010. Male sex, young age, marriage, partial resection, grade II/III tumors, and large tumors predicted for use of adjuvant therapy. For all patients, SRS improved survival compared with craniotomy alone. For patients with incomplete resection, SRS improved survival compared with craniotomy alone and adjuvant XRT. Randomized, prospective clinical trials are needed to better define the role of adjuvant XRT or SRS.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Related Content